Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
about
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysisAdverse safety events in patients with Chronic Kidney Disease (CKD).Anticoagulation Therapy in Patients with Chronic Kidney Disease.Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital.Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Anticoagulation in chronic kidney disease patients-the practical aspects.Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years oldPrevention and treatment of venous thromboembolism in the elderly patientEconomic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome.Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising eventsLow-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.Safety evaluation of enoxaparin in currently approved indications.Dosing low molecular weight heparins in kidney disease.Promise of factor Xa inhibition in acute coronary syndromes.Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients.High-Risk Non-ST Elevation Acute Coronary Syndrome Outcomes in Patients Treated with Unfractionated Heparin Monitored Using Anti-Xa Concentrations Versus Activated Partial Thromboplastin Time.Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of ECurrent dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey.Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.A need for evidence-based clinical practice guidelines for the use of heparins in the elderly.Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.Clinical decision support implemented with academic detailing improves prescribing of key renally cleared drugs in the hospital setting.Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome.Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study.Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin.Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase.Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention
P2860
Q26853150-93B736F9-43EB-4069-9D17-EA657660993BQ30245199-3B9ACA5F-95DE-4B12-BA1A-6B618616093AQ33435357-67D551FA-F639-4939-BEDF-0542AC6B65FCQ34503038-D0142348-925C-46C6-9F83-6BB0D214F6ABQ35154142-91C3E507-5024-46E1-B6B2-52A155C825AFQ35232128-EBBFDFCD-1618-46FB-B087-B18FF7759C4EQ35826954-157FC5F0-0154-4D03-8358-3A832AA9F69CQ36102602-242B1F7A-BE5B-4CD7-B116-0EA4DFA9B08DQ37017407-CEA56670-121C-4B3E-AA46-3A552232DA32Q37030849-93539264-1175-4506-8C0A-E7CBAB09D463Q37471067-8FFEC318-C08B-44F7-95ED-1239B7C8EE85Q37490581-06699ADC-3B2A-403D-AA4C-156AE4B1A4D1Q37622250-F464B024-B0E5-4697-A0CD-D88854BC43A6Q37867276-3BE98AD4-53E5-4BA0-9BB7-6D8A88B483C5Q37955861-4BBC4C3C-26BC-49EC-BF62-F6859D405EC3Q38124014-8D033C8A-C878-4839-810F-A3D6E839D6B9Q38168477-51CD592C-F8EF-44E2-9828-546D44603741Q38178237-12B03BF8-D92D-4935-A555-207A9D25EE35Q38656364-BFD07991-15D5-43FE-A496-80902DFA7FACQ40067699-CA991400-AF4D-406B-A70E-23E1D3757679Q40170302-CCD15277-58E7-488E-A4E0-9DBF243341A6Q40270973-BEA0817A-AED5-4DC7-9F37-1DD0C9A6B91DQ40673191-B3D21137-E9C8-47F4-AE72-B85425C2C7C5Q41314653-39AC9974-5C9A-4028-B337-3E572782D62FQ41807158-5B516C75-B5FA-46C7-8B62-122BE539D67AQ44557763-E7742580-E388-4EFA-AD65-AF00414E50DCQ46831995-913EB2D9-0353-4506-BFC0-3E5AE963AEAEQ51322589-6160EA02-3B70-49B6-94F6-D518E9F4A6BFQ53656617-0C463537-ADEB-4CF7-B4FA-B8F55C7B29B4Q56837771-16643F95-47AC-4A3B-A129-5B1F916E403D
P2860
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Anti-Xa activity relates to su ...... ients treated with enoxaparin.
@en
Anti-Xa activity relates to su ...... ients treated with enoxaparin.
@nl
type
label
Anti-Xa activity relates to su ...... ients treated with enoxaparin.
@en
Anti-Xa activity relates to su ...... ients treated with enoxaparin.
@nl
prefLabel
Anti-Xa activity relates to su ...... ients treated with enoxaparin.
@en
Anti-Xa activity relates to su ...... ients treated with enoxaparin.
@nl
P2093
P1433
P1476
Anti-Xa activity relates to su ...... ients treated with enoxaparin.
@en
P2093
Choussat R
P304
P356
10.1161/01.CIR.0000136830.65073.C7
P407
P577
2004-07-12T00:00:00Z